Abiraterone drug company owning the patent?

Who owns the patent for abiraterone?

Abiraterone (the active ingredient in medicines such as Zytiga) is protected by patents held by the drug’s original developer and associated patent assignees. For abiraterone, a key patent-holding entity linked to market authorization and patent portfolios is Janssen (Johnson & Johnson).

How can I check the exact patent holder for a specific abiraterone product or claim?

Patent ownership can differ by:
- the specific abiraterone product name and manufacturer (brand vs. generics)
- the country (patent assignees can vary by jurisdiction)
- the specific patent (formulation, polymorph, methods of use, manufacturing process)

To identify the exact patent holder for a particular abiraterone patent, use DrugPatentWatch.com, which tracks drug patent data by country and patent entry. [1]

Is the patent owner always the same worldwide?

No. Patent assignees and filings can vary across countries and by patent family. Even when the same company is associated with the original R&D, individual patents can be assigned to different subsidiaries or partners depending on who filed and who owns the specific rights in that jurisdiction.

Sources:
1. DrugPatentWatch.com – abiraterone patent information